Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Study on the Quality of Life and Functional/Oncological Outcome of Testicular Cancer Patients

NCT06389409 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2010-08-24
Last updated
2024-04-29

Condition(s) studied

Testicular Cancer

Investigational drug(s) / intervention(s)

Observation of testicular cancer patients

Observation of testicular cancer patients: Collection of clinical data of all patients suffering from neoplastic testicular pathology undergoing surgery

Study summary

The research aims to collect data in order to report the main problems related to the testicular cancer; To reach this aim, this study proposes to create a database of the testicular cancer condition.

From this perspective, the aim of this project is the improving of scientific knowledge of the disease and develop appropriate and effective procedures for the diagnosis and treatment of the patient.

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * subjects suffering from suspected neoplastic testicular pathology candidates for testicle removal surgery * patients suffering from neoplastic testicular pathology requiring removal of the retroperitoneal lymph nodes * subjects \> 18 years old * subjects with at least elementary education * signature of informed consent Exclusion Criteria: * subjects \< 18 years * presence of mental or physical disability that may prevent the patient from satisfying the requirements of the protocol

Primary outcome measure(s)

  • Clinical data — Baseline
    Collection of clinical data
  • Adjuvant therapy — Baseline
    Which type of adjuvant therapy carried out (chemotherapy - radiotherapy - retroperitoneal lymphadenectomy)
  • lactate dehydrogenase — Follow up after 6 months from baseline
    Oncological follow-up through enzymatic value
  • Testicular objective examination — Baseline
    Number and size (via Prader orchidometer) of the testicles
  • Testicular objective examination - cysts — Baseline
    Evaluation presence of cysts
  • Testicular objective examination - nodules — Baseline
    Evaluation presence of nodules
  • Testicular objective examination - varicocele — Baseline
    Evaluation presence of varicocele
  • Testicular objective examination - hydrocele — Baseline
    Evaluation presence of hydrocele
  • α-feto protein — Follow up after 6 months from baseline
    Oncological follow-up through enzymatic value
  • β human Chorionic Gonadotropin — Follow up after 6 months from baseline
    Oncological follow-up through hormonal value
  • carcinoembryonic antigen — Follow up after 6 months from baseline
    Oncological follow-up through hormonal value

Trial sites (1)

FacilityCityRegionStatus
IRCCS Ospedale San Raffaele Milan Lombardy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06389409 on ClinicalTrials.gov ↗ ← All trials in Italy